Therapies using ACCV can enhance
a patient's immune system's ability
to attack invading cancer cells...
cancer cells remaining after surgery,
radiation and/or chemotherapy
have failed.
ACCV are obtained
by processing a patient's tumor specimen
and separating the lymphocytes from
the cancer cells. These cancer cells
are grown in the laboratory. After
weeks of closely monitored growth,
the resulting ACCV are prepared for
patient treatment.
An average ACCV growth by CTI
produces sufficient vaccine for
4-10 injections.
CTI can provide
an established treatment protocol
and nursing procedure guidelines.
CTI
can provide orientation and training
of selected client personnel if
desired.
Dr. Robert K. Oldham is
available to discuss specific patient
details
BENEFITS
Can stimulate the patient's immune
system to attack invading cancer cells
and has the potential to generate a
clinical response.
Enhances
the hospital's ability to participate
in clinical trials.
Can contribute
to increasing the hospital's patient
census.
Provides a competitive advantage
for the local treatment facility.
ELIGIBILITY CRITERIA
ACCV therapy can
be considered for patients having a malignancy,
except for those whose physical or mental
conditions, in the opinion of their physician,
rule out cell-related therapies.
Specific emphasis should be placed
on melanoma and renal cell carcinoma.
Patients
requiring re-operations due to failed
treatments involving surgery, chemiotherapy
and radiation therapy are prime candidates
for ACCV.
BILLING
Service
Research
Service Charge
Cryopreservation and Processing
$1,250
ACCV
Feasibility
(cannot
occur until after cryopreservation
/ processing)
$1,950
ACCV
Growth
(4-10 treatments)
$3,750
Footnotes:
Average tumor size
cryopreserved is 3.5
grams.
Greater than
50% success rate for
growing ACCV from a
varying range of tumor
types and sizes.
Average
number of cancer cells
cryopreserved after
completion of a ACCV
Feasibility equals 1.5
x 109.
Average ACCV
growth produces 5 x
109 cells. (4-10 treatments).
Cancer
Therapeutics, Inc.™ (CTI)
is a leader in activated cell technology
offering Autologous
Tumor Cell Vaccines.
